

Mesoblast Ltd (MSB) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/M7F0DFB2EAC8EN.html>

Date: October 2021

Pages: 60

Price: US\$ 125.00 (Single User License)

ID: M7F0DFB2EAC8EN

Abstracts

Mesoblast Ltd (MSB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Mesoblast Ltd (Mesoblast) is a regenerative medicine company that develops regenerative cell-based products. Its most advanced candidate remestemcel-L is in development phase under the brand name RYONCIL for the treatment of pediatric steroid-refractory acute graft versus host disease (SR-aGVHD). Mesoblast is advancing rexlemestrocel for localized inflammatory diseases including advanced heart failure, end-stage ischemic heart failure, and MPc-06-ID (rexlemestrocel) for the treatment of chronic low back pain. The company employs its proprietary technology platform, mesenchymal lineage adult stem cells (MLCs), to discover and treat cardiac diseases, and hematological diseases, spine and musculoskeletal disorders and immune-mediated and inflammatory conditions. The company has operations in the US, Australia and Singapore. Mesoblast is headquartered in Melbourne, Victoria, Australia.

Mesoblast Ltd Key Recent Developments

Aug 30,2021: MSB Annual Financial Results and Operational Progress

Aug 30,2021: Mesoblast Announces Operational **Highlights** & Financial Results for the Year Ended June 30, 2021

Aug 10,2021: Mesoblast : Management changes post-financial year end

Jul 15,2021: Mesoblast presents respiratory function results of COVID-19 ARDS trial at

pulmonary disease conference

Jun 30,2021: Operational **Highlights** and Financial Results for the Year Ended June 30, 2021

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Mesoblast Ltd - Key Facts
Mesoblast Ltd - Key Employees
Mesoblast Ltd - Key Employee Biographies
Mesoblast Ltd - Major Products and Services
Mesoblast Ltd - History
Mesoblast Ltd - Company Statement
Mesoblast Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Mesoblast Ltd - Business Description
Business Segment: Commercialization Revenue
Performance
Business Segment: Interest Revenue
Performance
Business Segment: Milestone Revenue
Performance
R&D Overview
Mesoblast Ltd - Corporate Strategy
Mesoblast Ltd - SWOT Analysis
SWOT Analysis - Overview
Mesoblast Ltd - Strengths
Mesoblast Ltd - Weaknesses
Mesoblast Ltd - Opportunities
Mesoblast Ltd - Threats
Mesoblast Ltd - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart

Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Mesoblast Ltd, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 30, 2021: MSB Annual Financial Results and Operational Progress
Aug 30, 2021: Mesoblast Announces Operational Highlights & Financial Results for the Year Ended June 30, 2021
Aug 10, 2021: Mesoblast : Management changes post-financial year end
Jul 15, 2021: Mesoblast presents respiratory function results of COVID-19 ARDS trial at pulmonary disease conference
Jun 30, 2021: Operational Highlights and Financial Results for the Year Ended June 30, 2021
Jun 03, 2021: Mesoblast Corporate Update and Financial Results Webcast
Jun 02, 2021: Mesoblast Provides Operational Highlights and Financial Results for the Period Ended March 31, 2021
Apr 29, 2021: Mesoblast: Appendix 4C quarterly activity report
Mar 31, 2021: Mesoblast operational highlights and upcoming milestones
Mar 29, 2021: Philip J. Facchina, Chief Strategy Officer and Principal of SurgCenter Development, Joins Mesoblast Board

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Mesoblast Ltd, Key Facts
Mesoblast Ltd, Key Employees
Mesoblast Ltd, Key Employee Biographies
Mesoblast Ltd, Major Products and Services
Mesoblast Ltd, History
Mesoblast Ltd, Other Locations
Mesoblast Ltd, Subsidiaries
Mesoblast Ltd, Key Competitors
Mesoblast Ltd, Ratios based on current share price
Mesoblast Ltd, Annual Ratios
Mesoblast Ltd, Annual Ratios (Cont...1)
Mesoblast Ltd, Annual Ratios (Cont...2)
Mesoblast Ltd, Interim Ratios
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Mesoblast Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Mesoblast Ltd, Performance Chart (2017 - 2021)

Mesoblast Ltd, Ratio Charts

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Mesoblast Ltd (MSB) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/M7F0DFB2EAC8EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M7F0DFB2EAC8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970